This is a dose-ranging, open-label, Phase 1-2a study of TLK286 in combination with Doxil in patients with platinum refractory or resistant ovarian cancer.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
28
M.D. Anderson Cancer Center
Houston, Texas, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.